Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 nov 2006 - 07:07
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Acquisition of SBL Vaccin AB and Offering of New Ordinary Shares
Bericht
Leiden, The Netherlands, November 21, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed an agreement for the acquisition of Stockholm-based SBL Vaccin AB (SBL) from 3i and SEB for a total consideration of €39.4 million in cash. It is expected that the acquistion will be completed on Thursday, November 23, 2006.
In addition, Crucell today announced that it intends to raise €80 million through the issue of new ordinary shares. The proceeds will be used to fund the acquisition of SBL, refinance the acquisition of Berna Products Corporation completed on October 2, 2006 and repay outstanding debt of Berna Biotech AG.
Datum laatste update: 27 juli 2024